Arief S. Gunawan, Donal P. McLornan, Bridget Wilkins, Katherine Waghorn, Yvette Hoade, Nicholas C. P. Cross, Claire N. Harrison. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. haematol [Internet]. 2017May31 [cited 2024Apr.27];102(6):e238-e240. Available from: https://haematologica.org/article/view/8117